STOCK TITAN

Nurix Therapeutics (NRIX) SEC Filings

NRIX NASDAQ

Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.

The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.

Rhea-AI Summary

For Nurix Therapeutics, Inc. (NRIX), Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. each report beneficial ownership of 5,371,629 common shares, or 4.9% of the class. The Master Fund directly holds the shares; Perceptive Advisors, its investment manager, and Joseph Edelman, its managing member, may each be deemed beneficial owners. Each reports shared voting and dispositive power over the shares and zero sole voting or dispositive power. The reported percentages are based on 109,249,814 shares outstanding as of September 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
ownership
-
Rhea-AI Summary

Nurix Therapeutics, Inc. (NRIX) is the subject of an amended ownership report stating that Vestal Point Capital, LP and Ryan Wilder reported shared beneficial ownership of 7,025,000 common shares, or 6.4% of the class. Vestal Point Capital is the investment adviser to the Vestal Point Fund and Account, and Wilder is its Chief Investment Officer and Managing Partner. The Fund and Account directly hold the reported shares and have the right to receive dividends or direct the receipt of sale proceeds. Both reporting persons reported shared voting and dispositive power over the shares. NRIX had 109,249,814 common shares outstanding as of September 30, 2026. The reporting persons state that the report is not an admission that they are beneficial owners for purposes of Section 13 of the Securities Exchange Act of 1934.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
ownership
-
Rhea-AI Summary

Nurix Therapeutics, Inc. (NRIX) common stock was reported as beneficially owned in the amount of 4,966,827 shares by Rubric Capital Management LP, investment adviser to certain funds and accounts, and David Rosen, managing member of Rubric Capital’s general partner. Both reported shared voting and dispositive power over the same position, equal to 4.55% of the class. The percentage is based on 109,249,814 shares outstanding as of September 30, 2026. The reporting persons stated that the report should not be construed as an admission that either is a beneficial owner for purposes of Section 13.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
ownership
Rhea-AI Summary

Nurix Therapeutics, Inc. was the subject of an amended Schedule 13G in which T. Rowe Price Associates, Inc. reported 4,570,774 shares, or 4.4% of the class, as beneficially owned as of September 30, 2026. The firm reported sole voting power over 4,422,815 shares and sole dispositive power over 4,570,774 shares, with no shared voting or dispositive power. It stated that the disclosure should not be construed as an admission of beneficial ownership and expressly denied such ownership; it also marked the category for ownership of 5% or less of the class.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
ownership
-
Rhea-AI Summary

Nurix Therapeutics, Inc. (NRIX) is the issuer in an amendment where Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin each report beneficial ownership of 6,000,000 common shares, or 5.49% of the class.

Each reports shared voting and dispositive power over 6,000,000 shares and zero sole voting or dispositive power. The identical reported positions are not additive. The percentage is based on 109,249,814 common shares outstanding as of September 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
ownership
-
Rhea-AI Summary

Nurix Therapeutics, Inc. common stock: FMR LLC reported beneficial ownership of 4,350,596 shares, or 4.2% of the class, as of September 30, 2026. Abigail P. Johnson reported the same beneficial ownership amount. FMR LLC reported sole voting power over 4,348,192 shares and sole dispositive power over 4,350,596 shares; Abigail P. Johnson reported no voting power and sole dispositive power over 4,350,596 shares. Other persons were identified as having rights to dividends or sale proceeds, but none was reported to have an interest exceeding 5% of the class.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
ownership
Rhea-AI Summary

Nurix Therapeutics, Inc. Chief Financial Officer Hans van Houte sold 4,769 shares of common stock on November 4, 2026, in two transactions: 3,300 shares at a weighted average price of $15.3824 and 1,469 shares at a weighted average price of $16.2018. Both sales were made under a Rule 10b5-1 trading plan previously adopted by Hans van Houte. The reported price ranges were $14.91–$15.89 and $15.91–$16.78, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
insider
-
Rhea-AI Summary

Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring sold 16,715 shares of common stock in three transactions on November 2 and 3, 2026, under a previously adopted Rule 10b5-1 trading plan. On November 2, she exercised options for 5,786 shares at $8.72 per share; her reported option position afterward was 105,465. The November 2 sales were 9,527 shares at a weighted average $25.7392 per share and 1,075 shares at $26.7628; on November 3, she sold 6,113 shares at a weighted average $25.8329.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
insider
-
Rhea-AI Summary

Nurix Therapeutics, Inc. (NRIX) officer Johannes van Houte reported a proposed sale of 4,769 common shares, with an aggregate market value of $123,135.58 and an approximate sale date of November 4, 2026. Morgan Stanley Smith Barney LLC is listed as broker and NASDAQ as the exchange. The notice also reports 2,834 common shares sold for $74,474.97 during the prior three months and lists 4,769 common shares acquired from the issuer on October 30, 2026, in a transaction described as restricted stock units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
other
Rhea-AI Summary

Nurix Therapeutics, Inc. (NRIX) officer Christine Ring reported a proposed sale of 6,113 common shares, listed at an aggregate market value of $157,104.10. Morgan Stanley Smith Barney LLC is named as the broker. The acquisition details list restricted stock units dated October 30, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.23%
Tags
other

FAQ

How many Nurix Therapeutics (NRIX) SEC filings are available on StockTitan?

StockTitan tracks 128 SEC filings for Nurix Therapeutics (NRIX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Nurix Therapeutics (NRIX)?

The most recent SEC filing for Nurix Therapeutics (NRIX) was filed on November 16, 2026.